Fenetylline: Therapeutic use, misuse and/or abuse

Fenetylline (CAPTAGON ®) is included in a list of compounds to be considered by a World Health Organization (WHO) Expert Committee in April 1985 for possible international scheduling under the Convention on Psychotropic Substances, 1971. For over 23 years, this central stimulant has been used therap...

Full description

Saved in:
Bibliographic Details
Published in:Drug and alcohol dependence 1986-06, Vol.17 (2), p.259-271
Main Authors: Kristen, Gerfried, Schaefer, Annelies, Von Schlichtegroll, Ansgar
Format: Article
Language:English
Subjects:
Aged
Amphetamine
Amphetamines - adverse effects
Amphetamines - pharmacology
Amphetamines - therapeutic use
Applied sciences
Attention Deficit Disorder with Hyperactivity - drug therapy
Benefit/risk ratio
Biological and medical sciences
Child
Exact sciences and technology
Fenetylline
Germany, West
Humans
Hyperkinesis
Medical sciences
Misuse, Abuse
Narcolepsy - drug therapy
Neuropharmacology
Other techniques and industries
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Substance-Related Disorders - epidemiology
Theophylline - adverse effects
Theophylline - analogs & derivatives
Theophylline - therapeutic use
Therapeutic uses
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fenetylline (CAPTAGON ®) is included in a list of compounds to be considered by a World Health Organization (WHO) Expert Committee in April 1985 for possible international scheduling under the Convention on Psychotropic Substances, 1971. For over 23 years, this central stimulant has been used therapeutically in hyperkinetic children and other indications in place of amphetamines and other central stimulants with higher risk levels. In good correspondence with recent animal data fenetylline also shows significant qualitative and quantitative differences compared to amphetamine in man. It has few adverse side effects, a lower abuse potential and little actual abuse compared to amphetamine. Thus its benefit/risk assessment is substantially more favourable than that of other central stimulants. For proper therapeutic use of the substance, prescription status is or should be required by national authorities.
ISSN:0376-8716
1879-0046
DOI:10.1016/0376-8716(86)90012-8